Cargando…

PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL

Detalles Bibliográficos
Autores principales:	Sun, Xiuhua, Wang, Tingyu, Qiu, Lihua, Su, Hang, Cao, Junning, LI, Zhi-Ming, Song, Yuqin, Zhang, LI, LI, Dengju, Wu, Huijing, Zhang, Wei, LI, Junmin, Zhou, Keshu, Zhou, Hui, Yang, Yu, LI, Zhifeng, Cen, Hong, Cai, Zhen, Zhang, Zhihui, Fu, Weijun, Jin, Jie, LI, Fei, Wu, Weixin, Gu, Xuekui, Zhu, Weiliang, Liu, Lihong, LI, Zengjun, Yi, Shuhua, Qiu, Lugui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428812/ http://dx.doi.org/10.1097/01.HS9.0000975808.46591.f9

Ejemplares similares

PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Qiu, Lihua, et al.
Publicado: (2023)

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
por: Wang, Tingyu, et al.
Publicado: (2023)

P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
por: wang, T., et al.
Publicado: (2022)

Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China
por: Li, Heng, et al.
Publicado: (2017)

MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Model-based clustering for identifying disease-associated SNPs in case-control genome-wide association studies
por: Xu, Yan, et al.
Publicado: (2019)

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
por: Zhi-Ming, LI, et al.
Publicado: (2023)

A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
por: Song, Yuqin, et al.
Publicado: (2022)

A(2A)R Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model
por: Huang, Jiaqi, et al.
Publicado: (2020)

Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies
por: Jiang, Bo, et al.
Publicado: (2021)

2269 Day-to-day association between alcohol use and physical activity in university students
por: Graupensperger, Scott, et al.
Publicado: (2018)

Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China
por: Li, Zengjun, et al.
Publicado: (2015)

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist
por: Bai, Yu, et al.
Publicado: (2022)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study
por: Zha, Jie, et al.
Publicado: (2023)

2269. Clinical Outcomes in Patients with Carbapenem-Non-Susceptible, β-Lactam-Susceptible Pseudomonas aeruginosa Infections
por: Gavaghan, Victoria M, et al.
Publicado: (2019)

Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis
por: Yi, Shuhua, et al.
Publicado: (2020)

Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region
por: Yi, Shuhua, et al.
Publicado: (2017)

Drawing the tree of eukaryotic life based on the analysis of 2,269 manually annotated myosins from 328 species
por: Odronitz, Florian, et al.
Publicado: (2007)

2269. Inpatient Antibiotic Prescribing for Symptomatic COVID-19 Patients in a Large US Sample, 2020-2022
por: Pulia, Michael, et al.
Publicado: (2023)

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
por: An, Gang, et al.
Publicado: (2021)

Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
por: Hao, Mu, et al.
Publicado: (2016)

PB2269: HUMORAL AND T-CELL RESPONSES TO SARS-COV2 VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA MANAGED IN THE COMMUNITY SETTING
por: Holik, H., et al.
Publicado: (2022)

Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH
por: Zang, Meirong, et al.
Publicado: (2015)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

PReS-FINAL-2269: Incidence of antiphospholipid antibody syndrome in a cohort of children suffering from either arterial or venous thrombosis
por: Cancarini, P, et al.
Publicado: (2013)

Correction: Okomo-Adhiambo, M. et al. Neuraminidase Inhibitor Susceptibility Testing in Human Influenza Viruses: A Laboratory Surveillance Perspective. Viruses 2010, 2, 2269–2289
por: Okomo-Adhiambo, Margaret, et al.
Publicado: (2011)

Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China
por: Zha, Jie, et al.
Publicado: (2021)

Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia
por: Zhang, Ye, et al.
Publicado: (2016)

Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders
por: Yi, Shuhua, et al.
Publicado: (2017)

Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
por: Xiong, Wenjie, et al.
Publicado: (2023)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023)

Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma
por: Li, Fei, et al.
Publicado: (2015)

Cryptic non-canonical splice site activation is part of the mechanism that abolishes multimer organization in the c.2269_2270del von Willebrand factor
por: Daidone, Viviana, et al.
Publicado: (2020)

Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
por: Jing, Hongmei, et al.
Publicado: (2022)

c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation
por: Wu, Guixian, et al.
Publicado: (2018)

Analysis and Research on Starch Content and Its Processing, Structure and Quality of 12 Adzuki Bean Varieties
por: Zhang, Lei, et al.
Publicado: (2022)

Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
por: Song, Yuqin, et al.
Publicado: (2023)

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors
por: Cao, Yang, et al.
Publicado: (2016)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
por: Li, Ru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_evfhsvo03bj09j0rrt2h3cgjgp